Expert Q&As
Expert Q&A - 1st Interactions with European Medicine Agency
What are the different regulatory pathways available when expanding to Europe and which one is the best fit for me?
Access decades of experience

What’s Inside the Q&A:
Pathway Decision Framework
Identify which of the four regulatory routes fits your product type and commercial strategy.
Timeline & Coverage Comparison
Side-by side breakdown review periods, country coverage, and resulting licenses for each pathway option.
Mandatory vs. Optional Routes
Understanding when you have no choice (biotechnology, orphan drugs) versus when you control the decision and timing.
Multi-Pathway Approach
How to combine different pathways (starting with DCP, then using MRP for expansion) for optimal market coverage.
Download our Expert Q&A
Discover our latest news

White Papers
5 Critical Considerations before your first EMA interaction
Get all the business experience needed for a successful first EMA interaction.

Case Studies
Fast-tracking Market Entry to France
Discover how a Pharmaceutical Company can Cut 18 months off the Standard Timeline.
Articles
Launching of AzurBio Consulting
AzurBio Pharma Strengthens Its Foothold in European Regulatory Services with the Acquisition of A-pharmaconsult, Launching AzurBio Consulting.